

Materials for this course will release 09/14/2022

Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 2A-B (Cert # L229131)

Teaser: This course is a collection of journal articles that focus on advances across the oncology specialty practice domains. It is a series of current articles from the primary oncology literature.

Tag: Certifications; Oncology



ACPE Numbers: Various – see listing below

Pre-Sale Date: 08/24/2022

Content Release Date: 09/14/2022

Expiration Date: 03/14/2023

Activity Type: Application-based

CE Credits: 8 contact hours

Activity Fee: \$160 (ASHP member); \$215 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

- Acute Leukemia
- Breast Cancer
- Cancer-related Infectious Diseases
- Colon Cancer
- Hematopoietic Stem Cell Transplantation
- Lymphoma
- Lung Cancer
- Prostate Cancer

Activity Overview

The Home Study Syllabus is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice.

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

Materials for this course will release 09/14/2022

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact Hours	Assessment Pass Point
Oncology Home Study Syllabus Module 2A: Lymphoma, Acute Leukemia, Cancer-related Infectious Diseases, Hematopoietic Stem Cell Transplantation	0204-9999-22-954-H01-P	4.0 ACPE	76%
Oncology Home Study Syllabus Module 2B: Breast Cancer, Colon Cancer, Lung Cancer, Prostate Cancer	0204-9999-22-955-H01-P	4.0 ACPE	76%
Recertification Assessment Group 1		8.0 BPS	

Articles and Learning Objectives

Oncology Home Study Syllabus Module 2A: Lymphoma, Acute Leukemia, Cancer-related Infectious Diseases, Hematopoietic Stem Cell Transplantation

ACPE #: 0204-9999-22-954-H01-P

This module focuses on oral therapy options for acute myeloid leukemia, *Clostridioides difficile* infection treatment in adults, treatment for previously untreated diffuse large B-cell lymphoma, and evaluation of an option for prevention of acute graft versus host disease

Tilly H, Morschhauser F, Sehn LH et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med.* 2022;386:351-363.

Learning Objectives:

- Describe the POLARIX study of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) for the first-line treatment of diffuse large B-cell lymphoma.
- Develop recommendations for the use of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) for the first-line treatment of diffuse large B-cell lymphoma.

Wei AH, Döhner H, Pocock C et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. *N Engl J Med.* 2020;383(26):2526-2537.

Learning Objectives:

- Analyze the efficacy and safety data for the use of oral azacitidine maintenance to treat patients with acute myeloid leukemia.
- Select appropriate supportive care and monitoring strategies for patients treated with oral azacitidine.
- Choose appropriate therapy for patients with acute myeloid leukemia based on the results of the QUAZAR AML-001 trial.

Materials for this course will release 09/14/2022

Watkins B, Qayed M, McCracken C et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. *J Clin Oncol.* 2021;39:1865-1877.

Learning Objectives:

- Describe the study of abatacept for acute graft-versus-host disease (GVHD) prevention in allogeneic hematopoietic cell transplant.
- Develop recommendations for the use of abatacept in allogeneic hematopoietic cell transplant for prevention of acute GVHD.
- Evaluate study design for treatment regimens for prevention of GVHD.

Johnson S, Lavergne V, Skinner AM et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of *Clostridioides difficile* infection in adults. *Clin Infect Dis.* 2021;73:e1029-e1044.

Learning Objectives:

- Describe the 2021 focused update of the clinical practice guideline from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) for the management of *Clostridioides difficile* infection in adults.
- Develop recommendations for the management of initial and recurrent *Clostridioides difficile* infection episodes in adults.
- Select appropriate patients to receive bezlotoxumab based on the IDSA/SHEA guidelines.

Oncology Home Study Syllabus Module 2B: Breast Cancer, Colon Cancer, Lung Cancer, Prostate Cancer

ACPE #: 0204-9999-22-955-H01-P

This module focuses on endocrine treatment and targeted therapy for metastatic breast cancer; the effect of celecoxib, added to standard adjuvant therapy, on stage III colon cancer; treatment options for unresectable malignant pleural mesothelioma, and the ASCO Guideline update for initial management of noncastrate advanced, recurrent, or metastatic prostate cancer.

Virgo KS, Rumble RB, de Wit R et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. *J Clin Oncol.* 2021;39(11):1274-1305.

Learning Objectives:

- Apply the principles of the ASCO Guidelines to education of patients with noncastrate prostate cancer.
- Formulate a patient-specific treatment plan based on the ASCO Guidelines for men with noncastrate prostate cancer.
- Evaluate the risks and benefits of various treatment strategies used in the initial management of noncastrate prostate cancer.

Materials for this course will release 09/14/2022

Burstein HJ, Somerfield MR, Barton DL et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer: ASCO guideline update. *J Clin Oncol.* 2021;39:3959-3977.

Learning Objectives:

- Develop treatment recommendations for individual patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer based on the American Society of Clinical Oncology (ASCO) guidelines.
- Interpret results from key clinical trials in patients with HR-positive, HER2-negative metastatic breast cancer which informed the ASCO guidelines.
- Evaluate potential adverse effects and monitoring strategies for patients receiving endocrine and targeted therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.

Meyerhardt JA, Shi Q, Fuchs C et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer. The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. *JAMA.* 2021;325(13):1277-1285.

Learning Objectives:

- Interpret the results of the CALGB/SWOG 80702 trial.
- Counsel patients or other health care providers on the utility of celecoxib in the adjuvant setting for stage III colon cancer.
- Identify the limitations of the CALGB/SWOG 80702 trial.

Bass P, Scherpereel A, Nowak AK et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicenter, randomised, open-label, phase 3 trial. *Lancet.* 2021;397:375-386.

Learning Objectives:

- Describe the CheckMate 743 trial of nivolumab plus ipilimumab for patients with unresectable, malignant pleural mesothelioma.
- Develop recommendations for the use of nivolumab plus ipilimumab in patients with unresectable, malignant pleural mesothelioma based on the results of the CheckMate 743 trial.
- Select appropriate patients to receive nivolumab plus ipilimumab based on the results of the CheckMate 743 trial.

Faculty (<https://www.rxcertifications.org/Oncology/Course-Faculty>)

Jessica Auten, PharmD, BCOP
Clinical Pharmacy Specialist, Acute Care Malignant Hematology
UNC Medical Center
Chapel Hill, North Carolina

Courtney C. Cavalieri, PharmD, BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Brette Conliffe, PharmD, BCOP
Clinical Oncology Pharmacist
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky

Karen M. Fancher, PharmD, BCOP*
Associate Professor of Pharmacy Practice/ Clinical Pharmacy Specialist - Oncology
Duquesne University School of Pharmacy/University of Pittsburgh Medical Center Passavant Hospital
Pittsburgh, Pennsylvania

Materials for this course will release 09/14/2022

Lauren Ice, PharmD, BCOP, BCPS
Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan

Janelle Mann, PharmD, BCOP
Clinical Oncology Pharmacist/Manger, Clinical Pharmacy
Services
Alvin J. Siteman Cancer Center/Washington University
School of Medicine in St. Louis
St. Louis, Missouri

Anthony J. Perissinotti, PharmD, BCOP
Hematology Clinical Pharmacist Specialist
University of Michigan – Michigan Medicine
Ann Arbor, Michigan

Danielle Roman, PharmD, BCOP*
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

***Content Matter Experts**

Reviewers

Angela T. Cassano, PharmD, BCPS, FASHP

Field Testers

Megan Adami, PharmD, BCOP
Bailee Binks, PharmD, BCOP
Susan Chacko, PharmD, BCOP
Charleen Colletta, PharmD, BCOP
Brette Conliffe, PharmD, BCOP
Binh Diep, PharmD, BCOP
Walter Domingo, PharmD, BCOP
Karen Fancher, PharmD, BCOP
Robert Grabowski, PharmD, BCOP
Elizabeth Hageman, PharmD BCPS, BCOP
Kristin Herald, PharmD, BCPS, BCOP
Annie Ho, PharmD, BCOP
Mitchell Hughes, PharmD, BCPS, BCOP
Raymond Iannuccillo, PharmD, MBA, BCPS, BCOP
Lauren Ice, PharmD, BCPS, BCOP
Jeremiah Jessee, PharmD, BCOP
Bonnie Labdi, PharmD, BCOP
Matthew Lariviere, PharmD, BCOP
Jessica Lewis-Gonzalez, PharmD, BCOP
Andrew (Weiyi) Li, PharmD, BCOP
Barbara Li, PharmD, BCOP

Suwicha Limvorasak, PharmD, BCOP
Katherine Lin, BS, PharmD, BCOP
Amanda Lucky, PharmD, BCPS, BCOP
Robert Luschen, PharmD, BCOP
Alia Lynch, PharmD, BCOP
Mostafa Morsy, BPharm, PharmD, PgDi, BCOP
Carol Peek, PharmD, BCOP
Yoon Sun Ree, MS, BCOP
Glenn Roma, PharmD, PhD, BCOP
Andrew Sam, PharmD, MBA, BCOP
Gregory Sneed, PharmD, BCOP
Mellissa Taylor, PharmD, BCOP
Marin Touchstone, PharmD, BCOP
Angela Urmanski, PharmD, BCOP
Christine Walko, PharmD, BCOP, FCCP
Kristin Wenzel, PharmD, BCOP
Stephanie Willenbring, PharmD, MPH, BCOP
Abu Bakr Yousif, BPharm, MSc, BCOP
Jennifer Zadlo, PharmD, BCOP
Mark Zangardi, PharmD, BCOP
Kelsey Zielke, PharmD, BCPS, BCOP

Disclosures

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

Materials for this course will release 09/14/2022

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity's content have relevant financial relationships:

Karen M. Fancher: Consultant, AstraZeneca, LP; consultant, Merck & Co.

Anthony Perissinotti: Consultant, Amgen; consultant, Pfizer; consultant, Servier

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

ASHP and ACCP collaborate on oncology activities.